via pharmatimes.com
The announcement came hours after the Financial Times Deutschland had reported that Merck would not be extending Mr Schnee’s contract due in part to the clinical setbacks the firm has suffered of late. Last month, the US Food and Drug Administration extended its review period for the company’s multiple sclerosis pill cladribine, which was rejected by advisors to the European Medicines Agency in September.
No comments:
Post a Comment